WO2005083385A3 - Method of evaluating the therapeutic potential of a vaccine for mucosal administration - Google Patents

Method of evaluating the therapeutic potential of a vaccine for mucosal administration Download PDF

Info

Publication number
WO2005083385A3
WO2005083385A3 PCT/DK2005/000123 DK2005000123W WO2005083385A3 WO 2005083385 A3 WO2005083385 A3 WO 2005083385A3 DK 2005000123 W DK2005000123 W DK 2005000123W WO 2005083385 A3 WO2005083385 A3 WO 2005083385A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic potential
vaccine
evaluating
mucosal administration
vaccination
Prior art date
Application number
PCT/DK2005/000123
Other languages
French (fr)
Other versions
WO2005083385A2 (en
Inventor
Hans-Henrik Ipsen
Maerkedahl Lise Lund
Henrik Hugo Jacobi
Original Assignee
Alk Abello As
Hans-Henrik Ipsen
Maerkedahl Lise Lund
Henrik Hugo Jacobi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alk Abello As, Hans-Henrik Ipsen, Maerkedahl Lise Lund, Henrik Hugo Jacobi filed Critical Alk Abello As
Priority to CA002556557A priority Critical patent/CA2556557A1/en
Priority to EP05706785A priority patent/EP1718974A2/en
Priority to JP2007500050A priority patent/JP2007524096A/en
Priority to AU2005217696A priority patent/AU2005217696B2/en
Priority to BRPI0508078-9A priority patent/BRPI0508078A/en
Priority to RU2006134031/15A priority patent/RU2006134031A/en
Publication of WO2005083385A2 publication Critical patent/WO2005083385A2/en
Publication of WO2005083385A3 publication Critical patent/WO2005083385A3/en
Priority to IL177703A priority patent/IL177703A0/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)

Abstract

The invention relates to a method of evaluating the therapeutic potential of a vaccination program comprising a vaccine for mucosal administration comprising one or more antigens and a vaccination protocol, the method comprising a) subjecting at least one test individual to the vaccination program, b) measuring the level of a biomarker antibody selected from the group consisting of IgA, IgG, IgE and IgX specific to the antigen in a biological sample from the test individual, and c) using the measurements obtained to evaluate the therapeutic potential of the vaccination program.
PCT/DK2005/000123 2004-02-26 2005-02-24 Method of evaluating the therapeutic potential of a vaccine for mucosal administration WO2005083385A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA002556557A CA2556557A1 (en) 2004-02-26 2005-02-24 Method of evaluating the therapeutic potential of a vaccine for mucosal administration
EP05706785A EP1718974A2 (en) 2004-02-26 2005-02-24 Method of evaluating the therapeutic potential of a vaccine for mucosal administration
JP2007500050A JP2007524096A (en) 2004-02-26 2005-02-24 Method for evaluating the therapeutic potential of vaccines for mucosal administration
AU2005217696A AU2005217696B2 (en) 2004-02-26 2005-02-24 Method of evaluating the therapeutic potential of a vaccine for mucosal administration
BRPI0508078-9A BRPI0508078A (en) 2004-02-26 2005-02-24 method for assessing the therapeutic potential of a mucosal vaccine
RU2006134031/15A RU2006134031A (en) 2004-02-26 2005-02-24 METHOD FOR EVALUATING THE VACCINE THERAPEUTIC CAPACITY FOR INTRODUCTION THROUGH Mucous membranes
IL177703A IL177703A0 (en) 2004-02-26 2006-08-24 Method of evaluating the therapeutic potential of a vaccine for mucosal administration

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US54845404P 2004-02-26 2004-02-26
DKPA200400310 2004-02-26
DKPA200400310 2004-02-26
US60/548,454 2004-02-26
US55909504P 2004-04-02 2004-04-02
US60/559,095 2004-04-02

Publications (2)

Publication Number Publication Date
WO2005083385A2 WO2005083385A2 (en) 2005-09-09
WO2005083385A3 true WO2005083385A3 (en) 2005-11-17

Family

ID=34915878

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2005/000123 WO2005083385A2 (en) 2004-02-26 2005-02-24 Method of evaluating the therapeutic potential of a vaccine for mucosal administration

Country Status (8)

Country Link
EP (1) EP1718974A2 (en)
JP (1) JP2007524096A (en)
AU (1) AU2005217696B2 (en)
BR (1) BRPI0508078A (en)
CA (1) CA2556557A1 (en)
IL (1) IL177703A0 (en)
RU (1) RU2006134031A (en)
WO (1) WO2005083385A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005083385A2 (en) * 2004-02-26 2005-09-09 Alk-Abelló A/S Method of evaluating the therapeutic potential of a vaccine for mucosal administration
ATE522228T1 (en) 2007-03-28 2011-09-15 Alk Abello As USE OF AN EXCIPIENT-CONTAINING VACCINE FORMULATION FOR SUBCUTANEOUS ADMINISTRATION
CA2682054A1 (en) * 2007-03-28 2008-10-02 Alk-Abello A/S Use of an adjuvanted allergy vaccine formulation for parenteral administration
DE202008006598U1 (en) * 2008-04-11 2008-10-02 Alk-Abelló A/S Allergy vaccine formulation for mucosal administration
CN109952510A (en) 2016-05-13 2019-06-28 应用酵素医学研究所株式会社 Collect the method for predicting the data of all allergies risk

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992021031A1 (en) * 1991-05-10 1992-11-26 Alain De Weck PROCEDURE FOR DETECTING AND PREPARING ANTI-IgE AUTOANTIBODIES AND USE OF THESE ANTIBODIES AS ACTIVE AGENTS IN DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS
WO1998030586A2 (en) * 1997-01-13 1998-07-16 Oklahoma Medical Research Foundation Diagnostics and therapy of epstein-barr virus in autoimmune disorders
WO2000040713A1 (en) * 1999-01-06 2000-07-13 Mcmaster University Method of preventing immune and hypersensitivity reactions
WO2002053595A1 (en) * 2000-12-29 2002-07-11 Pharmacia Diagnostics Ab Group 2 allergen specific ige-fabs and igg molecules and use thereof
UA62780A (en) * 2003-05-22 2003-12-15 Univ Oo Bohomolets Nat Medical Method for estimating efficiency of vaccination against diphtheria in children with allergic diathesis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU228049B1 (en) * 1998-06-24 2012-09-28 Alk Abello As Method of detecting an antibody in a liquid sample
GB0215710D0 (en) * 2002-07-05 2002-08-14 Isis Innovation Diagnostic method
WO2005083385A2 (en) * 2004-02-26 2005-09-09 Alk-Abelló A/S Method of evaluating the therapeutic potential of a vaccine for mucosal administration

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992021031A1 (en) * 1991-05-10 1992-11-26 Alain De Weck PROCEDURE FOR DETECTING AND PREPARING ANTI-IgE AUTOANTIBODIES AND USE OF THESE ANTIBODIES AS ACTIVE AGENTS IN DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS
WO1998030586A2 (en) * 1997-01-13 1998-07-16 Oklahoma Medical Research Foundation Diagnostics and therapy of epstein-barr virus in autoimmune disorders
WO2000040713A1 (en) * 1999-01-06 2000-07-13 Mcmaster University Method of preventing immune and hypersensitivity reactions
WO2002053595A1 (en) * 2000-12-29 2002-07-11 Pharmacia Diagnostics Ab Group 2 allergen specific ige-fabs and igg molecules and use thereof
UA62780A (en) * 2003-05-22 2003-12-15 Univ Oo Bohomolets Nat Medical Method for estimating efficiency of vaccination against diphtheria in children with allergic diathesis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE EPODOC EUROPEAN PATENT OFFICE, THE HAGUE, NL; BYCHKOVA , N H: "Method for estimating efficiency of vaccination against diphteria in children with allergic diathesis", XP002344424 *

Also Published As

Publication number Publication date
AU2005217696A1 (en) 2005-09-09
JP2007524096A (en) 2007-08-23
AU2005217696B2 (en) 2008-02-14
RU2006134031A (en) 2008-04-10
EP1718974A2 (en) 2006-11-08
IL177703A0 (en) 2006-12-31
WO2005083385A2 (en) 2005-09-09
BRPI0508078A (en) 2007-07-17
CA2556557A1 (en) 2005-09-09

Similar Documents

Publication Publication Date Title
Crooke et al. Immunosenescence and human vaccine immune responses
Minervina et al. SARS-CoV-2 antigen exposure history shapes phenotypes and specificity of memory CD8+ T cells
Corbett et al. Immune correlates of protection by mRNA-1273 immunization against SARS-CoV-2 infection in nonhuman primates
Versteegh et al. Age-specific long-term course of IgG antibodies to pertussis toxin after symptomatic infection with Bordetella pertussis
MX2007014815A (en) Improved immunoassay methods.
WO2005083385A3 (en) Method of evaluating the therapeutic potential of a vaccine for mucosal administration
Renia et al. Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose
WO2005103698A3 (en) Methods and antibodies for nitrofuran detection
NO20076662L (en) Detection of a malantigen independent of the presence or absence of a corresponding therapeutic antibody
WO2012100070A3 (en) Methods and apparatus for detection of gluten sensitivity, and its differentiation from celiac disease
IN2009CN03372A (en)
Krämer et al. The rapid fluorescent focus inhibition test is a suitable method for batch potency testing of inactivated rabies vaccines
Muhamuda et al. Development and evaluation of a competitive ELISA for estimation of rabies neutralizing antibodies after post-exposure rabies vaccination in humans
Berbers et al. A novel method for evaluating natural and vaccine induced serological responses to Bordetella pertussis antigens
HK1094036A1 (en) Evaluation of adjuvanted vaccines
Rendi-Wagner et al. Antibody persistence following booster vaccination against tick-borne encephalitis: 3-year post-booster follow-up
Cliquet et al. Standardisation and establishment of a rabies ELISA test in European laboratories for assessing the efficacy of oral fox vaccination campaigns
Djagbare et al. Monoclonal antibody based in vitro potency assay as a predictor of antigenic integrity and in vivo immunogenicity of a Respiratory Syncytial Virus post-fusion F-protein based vaccine
WO2005106476A3 (en) Method for diagnosing infectious diseases
WO2006055422A3 (en) Sampling device and methods
Agrati et al. Coordinate induction of humoral and spike specific T-cell response in a cohort of Italian health care workers receiving BNT162b2 mRNA vaccine. Microorganisms 2021; 9: 1315
WO2005119259A3 (en) Population based prediction methods for immune response determinations and methods for verifying immunological response data
Thai et al. Seroepidemiology and serological follow-up of anti-leptospiral IgG in children in Southern Vietnam
Lai et al. Longitudinal neutralization activities on authentic Omicron variant provided by three doses of BBIBP‐CorV vaccination during one year
Hr et al. Analysis of specific antibody and cellular immune response to first-dose measles vaccine Edmonston-Zagreb in 9-month-old infants

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2556557

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 177703

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 4897/DELNP/2006

Country of ref document: IN

Ref document number: PA/a/2006/009737

Country of ref document: MX

Ref document number: 2007500050

Country of ref document: JP

Ref document number: 2005217696

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005706785

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006/07376

Country of ref document: ZA

Ref document number: 200607376

Country of ref document: ZA

ENP Entry into the national phase

Ref document number: 2005217696

Country of ref document: AU

Date of ref document: 20050224

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005217696

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006134031

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 200580011627.6

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005706785

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0508078

Country of ref document: BR